阿替唑单抗
医学
肿瘤科
三阴性乳腺癌
紫杉烷
内科学
吉西他滨
卡铂
化疗
蒽环类
临床终点
乳腺癌
转移性乳腺癌
免疫疗法
彭布罗利珠单抗
癌症
随机对照试验
顺铂
作者
Javier Cortés,Fabrice André,Anthony Gonçalvès,Sherko Kümmel,Miguel Martín,Peter Schmid,Florian Schuetz,Sandra M. Swain,Valerie Easton,Erika Pollex,Regula Deurloo,Rebecca Dent
出处
期刊:Future Oncology
[Future Medicine]
日期:2019-06-01
卷期号:15 (17): 1951-1961
被引量:61
标识
DOI:10.2217/fon-2019-0059
摘要
The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for PD-L1-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining atezolizumab with first-line nab-paclitaxel for metastatic TNBC significantly improved progression-free survival and showed a clinically meaningful effect on overall survival in patients with PD-L1-positive tumors. The placebo-controlled randomized Phase III IMpassion132 (NCT03371017) trial is evaluating atezolizumab with first-line chemotherapy (capecitabine [mandatory in platinum-pretreated patients] or gemcitabine/carboplatin) for inoperable locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy. Stratification factors are: visceral metastases, tumor immune cell PD-L1 status and selected chemotherapy. Patients are randomized to atezolizumab 1200 mg or placebo every 3 weeks with the chosen chemotherapy, continued until progression, unacceptable toxicity or withdrawal. The primary end point is overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI